title: Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM study.
abstract: It is now established that small dense low-density lipoproteins (LDLs) are more common among patients with coronary heart disease than among control individuals. Small LDL size is also associated with a high-risk profile, including increased levels of triglycerides and decreased high-density lipoprotein (HDL)-cholesterol. Furthermore, some human HDL particles contain both apolipoprotein (apo) A-I and apoA-II (LpA-I:A-II) while others contain apoA-I but are devoid of apoA-II (LpA-I). We have investigated the relationship between LDL size, measured by non-denaturing gradient-gel electrophoresis, and HDL parameters, particularly LpA-I and LpA-I:A-II levels, in healthy control subjects (n = 408). LDL size was positively and significantly correlated with HDL-cholesterol (r = 0.43), apoA-I (r = 0.32) and LpA-I (r = 0.29), whereas no correlation was observed with apoA-II and LpA-I:A-II. The determination of the mean apoA-I and LpA-I in the quintiles of LDL size distribution revealed a progressive increase in apoA-I and LpoA-I from the first quintile (small LDLs), 137 and 42 mg dL-1 respectively, to the fifth quintile (large LDLs), 161 and 54 mg dL-1 respectively. Conversely, no evolution of apoA-II and LpA-I:A-II was observed. Multivariate analysis showed that not only triglycerides, but also HDL-cholesterol, apoA-I and LpA-I, are determinants of LDL size, depending on the model used. Thus, part of the variation in size of LDLs is associated with the metabolism of HDL independently of that of triglycerides. Thus, a low concentration of LpA-I combined with the presence of small LDLs could contribute to the high-risk profile observed in subjects with small LDLs.
authors.affiliation: Department of Atherosclerosis, SERLIA and INSERM U325, Institut Pasteur de Lille, France.
authors.forename: G
authors.initials: G
authors.lastname: Luc
authors.forename: J M
authors.initials: JM
authors.lastname: Bard
authors.forename: P
authors.initials: P
authors.lastname: Poulain
authors.forename: D
authors.initials: D
authors.lastname: Arveiler
authors.forename: A E
authors.initials: AE
authors.lastname: Evans
authors.forename: F
authors.initials: F
authors.lastname: Cambien
authors.forename: J C
authors.initials: JC
authors.lastname: Fruchart
authors.forename: P
authors.initials: P
authors.lastname: Ducimetière
mesh_terms: D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood* / Q000737:chemistry; D016633:Apolipoprotein A-II / Q000097:blood / Q000737:chemistry; D016022:Case-Control Studies; D003327:Coronary Disease / Q000097:blood / Q000209:etiology; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood / Q000737:chemistry; D008075:Lipoproteins, HDL / Q000097:blood / Q000737:chemistry; D008077:Lipoproteins, LDL / Q000097:blood / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D012016:Reference Values; D012307:Risk Factors
chemical_list: D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D017270:Lipoprotein(a); D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL